Cargando…

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome

PURPOSE: Patients with myelodysplastic syndrome (MDS) are at risk of relapse after allogeneic hematopoietic cell transplantation. The utility of ultra-deep genomic testing to predict and the impact of conditioning intensity to prevent MDS relapse are unknown. METHODS: Targeted error-corrected DNA se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dillon, Laura W., Gui, Gege, Logan, Brent R., Fei, Mingwei, Ghannam, Jack, Li, Yuesheng, Licon, Abel, Alyea, Edwin P., Bashey, Asad, Devine, Steven M., Fernandez, Hugo F., Giralt, Sergio, Hamadani, Mehdi, Howard, Alan, Maziarz, Richard T., Porter, David L., Warlick, Erica D., Pasquini, Marcelo C., Scott, Bart L., Horwitz, Mitchell E., Deeg, H. Joachim, Hourigan, Christopher S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140814/ https://www.ncbi.nlm.nih.gov/pubmed/34036237 http://dx.doi.org/10.1200/PO.20.00355

Ejemplares similares

Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach
por: Courville, Elizabeth L., et al.
Publicado: (2017)

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study
por: Versluis, Jurjen, et al.
Publicado: (2023)

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy
por: Zimmerman, Zachary, et al.
Publicado: (2011)

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
por: McCormack, Steven E, et al.
Publicado: (2010)

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia
por: Gui, Gege, et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
por: Crees, Zachary D., et al.
Publicado: (2023)

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
por: Alessandrino, Emilio Paolo, et al.
Publicado: (2013)

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders
por: Symeonidis, Argiris, et al.
Publicado: (2022)

Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant
por: Solomon, Scott R., et al.
Publicado: (2023)

Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
por: Blau, Olga, et al.
Publicado: (2014)

Optimizing Management of the Central Nervous System in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplantation
por: Patel, Pranalee, et al.
Publicado: (2022)

Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis
por: Hamadani, Mehdi, et al.
Publicado: (2020)

Abstract 2 Results of an Open Label Expanded Access Study of Omidubicel-onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies
por: Horwitz, Mitchell, et al.
Publicado: (2023)

Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014
por: D’Souza, Anita, et al.
Publicado: (2017)

Fit Older Adults with Advanced Myelodysplastic Syndromes: Who is Most Likely to Benefit from Transplant?
por: Abel, Gregory A., et al.
Publicado: (2020)

Successful treatment of myelodysplastic syndrome and Behcet colitis after allogeneic hematopoietic stem cell transplantation
por: Kook, Min-Ha, et al.
Publicado: (2014)

Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
por: Choi, Eun-Ji, et al.
Publicado: (2018)

Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome
por: Belohlavkova, P, et al.
Publicado: (2021)

Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes
por: Wang, Wei, et al.
Publicado: (2021)

Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome
por: Zeng, Xiangzong, et al.
Publicado: (2021)

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
por: Baranwal, Anmol, et al.
Publicado: (2022)

Donor Cell-Derived Myelodysplastic Syndrome Following Allogenic Peripheral Blood Stem Cell Transplant
por: Narang, Ujjwala, et al.
Publicado: (2023)

Post-allogeneic stem cell transplant FLT3- targeted maintenance therapy: updates and considerations for clinical practice
por: Cohen, Jonathan, et al.
Publicado: (2022)

Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation
por: Deeg, H. Joachim
Publicado: (2022)

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
por: Gagelmann, Nico, et al.
Publicado: (2019)

Allogeneic hematopoietic stem cell transplantation for Crohn disease complicated with myelodysplastic syndrome: A case report
por: Zhang, Ying, et al.
Publicado: (2020)

Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes
por: Liu, Liu, et al.
Publicado: (2021)

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD
por: He, Fiona, et al.
Publicado: (2016)

Impact of Copy Neutral Loss of Heterozygosity and Total Genome Aberrations on Survival in Myelodysplastic Syndrome
por: Yeung, Cecilia, et al.
Publicado: (2017)

Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation
por: Asano, Takeru, et al.
Publicado: (2014)

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes
por: Falconi, Giulia, et al.
Publicado: (2018)

Discordant Response of Systemic Mastocytosis Associated With Myelodysplastic Syndrome After Midostaurin and Allogeneic Hematopoietic Stem-cell Transplantation
por: Haas, Marion, et al.
Publicado: (2020)

Room for Improvement: A 20-Year Single Center Experience with Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes
por: Duda, Katarzyna, et al.
Publicado: (2021)

Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration
por: Jain, Tania, et al.
Publicado: (2023)

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
por: Buckley, Sarah A., et al.
Publicado: (2017)

Multicenter Validation Study of a Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes
por: Armand, Philippe, et al.
Publicado: (2009)

Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome
por: Radujkovic, Aleksandar, et al.
Publicado: (2015)

Minimal Change Disease Secondary to Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndrome
por: Elghawy, Omar, et al.
Publicado: (2022)

Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation
por: Hemsing, Anette Lodvir, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9dm3ddpimhmtl7m1kcefd7td7e